Introduction
COVID-191 has spread around the world. With the
efforts of various countries and international organizations, the
epidemic has gradually controlled, but there are still no specific drugs
for COVID-19. Improving symptoms and preventing further exacerbation of
the disease has become critical to clinical treatment.
Most of studies have shown that D-Dimer levels in death with COVID-19
are increased significantly2, suggesting a possibility
of the complication of venous thromboembolism (VTE). Autopsy found many
microscopic lung thrombis3 and deep vein thrombosis
(DVT) rates up to 25% in severe COVID-19 clinical
findings4 indicating the risk of VTE is high in
COVID-19. The COVID-19 is highly infectious and pathogenic which has
increased health care workers’ exposure risk in traditional approach for
VTE diagnosis. In this special period, increasing the clinical awareness
and diagnosis of VTE, focusing on the occurrence of early-stage clinical
symptoms, using available laboratory test to evaluate the condition, and
beginning anticoagulant therapy early5 while ensuring
the safety is of great importance.
Current studies conducted that anticoagulant therapy can reduce COVID-19
mortality and improve patient prognosis6, but there
are separate opinions about the timing of preventive anticoagulant
therapy. Through the retrospective study, our team analyzed the dynamic
changes of D-dimer under different illness conditions and the prognosis
of anticoagulant therapy at different D-dimer levels. The aim of our
study was to analyze the clinical significance of D-Dimer in predicting
illness severity and guiding anticoagulant therapy in COVID-19.